Microbiome Approval Pathway Workshop Could Help Sort Out Probiotic Path
This article was originally published in The Rose Sheet
Executive Summary
FDA's regulatory pathway "for development of probiotic drugs is reasonably clear. But the road to develop probiotic foods, supplements or microbiome-based dietary strategies to compensate for deficient microbiota is less so," says the International Scientific Association for Probiotics and Prebiotics. FDA's Center for Biologics Evaluation and Research is conducting Sept. 17 workshop to exchange information with the scientific community about the clinical, manufacturing and regulatory considerations associated with live microbiome-based products administered to treat a disease.
You may also be interested in...
Pandemic Driving Stress In Consumers? DuPont Has A Probiotic Strain For That
HOWARU Calm contains probiotic strain Lpc-37 (L. paracasei) and can be added to supplements or formulated into new products, says DuPont Nutrition & Biosciences. It reports that 65% of adults worldwide are experiencing some daily stress.
DuPont Sees Immune Health Probiotic Sales Opening Window On More Microbial Use In Nutrition
While stockpiling for immune health support drove early sales growth in response to the pandemic, probiotic sales likely will continue increasing, says DuPont Nutrition probiotic marketing head Vanessa Bailey. “My gut tells me I think we could see some sustained increase. There’s going to be some difference in how we behave.”
FDA OK With Probiotic Weight CFUs In Supplement Facts Labels, For Now
Until CFSAN decides whether to engage in a rulemaking to amend FDA's supplement labeling regulation, it intends "to exercise enforcement discretion for those firms that choose to declare the quantitative amount of live microbial ingredients in the Supplement Facts label by CFUs in addition to weight," according to draft guidance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: